1. Home
  2. NXTC vs LITB Comparison

NXTC vs LITB Comparison

Compare NXTC & LITB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXTC
  • LITB
  • Stock Information
  • Founded
  • NXTC 2015
  • LITB 2007
  • Country
  • NXTC United States
  • LITB Singapore
  • Employees
  • NXTC N/A
  • LITB N/A
  • Industry
  • NXTC Biotechnology: Pharmaceutical Preparations
  • LITB Catalog/Specialty Distribution
  • Sector
  • NXTC Health Care
  • LITB Consumer Discretionary
  • Exchange
  • NXTC Nasdaq
  • LITB Nasdaq
  • Market Cap
  • NXTC 31.6M
  • LITB 33.9M
  • IPO Year
  • NXTC 2019
  • LITB N/A
  • Fundamental
  • Price
  • NXTC $0.89
  • LITB $1.60
  • Analyst Decision
  • NXTC Strong Buy
  • LITB
  • Analyst Count
  • NXTC 2
  • LITB 0
  • Target Price
  • NXTC $4.00
  • LITB N/A
  • AVG Volume (30 Days)
  • NXTC 218.5K
  • LITB 16.3K
  • Earning Date
  • NXTC 11-07-2024
  • LITB 12-10-2024
  • Dividend Yield
  • NXTC N/A
  • LITB N/A
  • EPS Growth
  • NXTC N/A
  • LITB N/A
  • EPS
  • NXTC N/A
  • LITB N/A
  • Revenue
  • NXTC N/A
  • LITB $333,093,000.00
  • Revenue This Year
  • NXTC N/A
  • LITB N/A
  • Revenue Next Year
  • NXTC N/A
  • LITB N/A
  • P/E Ratio
  • NXTC N/A
  • LITB N/A
  • Revenue Growth
  • NXTC N/A
  • LITB N/A
  • 52 Week Low
  • NXTC $0.87
  • LITB $1.47
  • 52 Week High
  • NXTC $2.57
  • LITB $6.84
  • Technical
  • Relative Strength Index (RSI)
  • NXTC 22.88
  • LITB 34.79
  • Support Level
  • NXTC $1.06
  • LITB $1.66
  • Resistance Level
  • NXTC $1.21
  • LITB $1.96
  • Average True Range (ATR)
  • NXTC 0.10
  • LITB 0.15
  • MACD
  • NXTC -0.02
  • LITB -0.00
  • Stochastic Oscillator
  • NXTC 5.21
  • LITB 12.50

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.

About LITB LightInTheBox Holding Co. Ltd.

LightInTheBox Holding Co Ltd is an online retail company delivering products directly to consumers across the world. It provides apparel products including customized, special occasion and fast fashion apparel products; and other general merchandise products, such as accessories and gadgets, home and garden products, electronics and communication devices, and other products. The company is engaged in product sales which consisted of online retailing of consumer products. It also provides services which consisted of the provision of logistic services to e-commerce retailers and small businesses. Geographically, it operates in Europe which is the key revenue driver, North America, and other countries.

Share on Social Networks: